ARD-103

N/A

Report date: 2025/01/17 15:10:55

Base Information

Drug NameARD-103

Drug Alias NameARD103ARD-103

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionC-Type lectin domain family 12 member A modulators

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesARCE Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesARCE Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A